ArticleCellular oncology (Dordrecht, Netherlands)2026
ASCL2 drives colorectal cancer metastasis through transcriptional activation of TDGF1.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeMetastasis underlies most colorectal cancer (CRC)-related deaths, yet its molecular drivers remain incompletely characterized. This study aims to provide novel insights into the mechanisms underlying CRC metastasis through integrated multiomics and experimental validation.
methodsMalignant epithelial cell subpopulations and key regulators of metastatic transition were identified through copy number variation inference and pseudotime trajectory analysis from CRC scRNA-seq data. Dual-luciferase reporter, chromatin immunoprecipitation, and functional studies were used for mechanistic validation in vitro. Tumor growth and metastatic capacity in vivo were evaluated using subcutaneous xenograft and tail vein injection-induced metastasis models. Clinical samples were analyzed to investigate the expression patterns of ASCL2 and TDGF1 during CRC clinical progression.
resultsScRNA-seq revealed a malignant tumor cell subpopulation undergoing differentiation toward metastasis. Pseudotime trajectory analysis revealed the transcription factor ASCL2 as a key regulator of metastatic transition, with its expression increasing during fate commitment from primary to metastatic states. ASCL2 directly binds the TDGF1 promoter to activate its transcription. Functional studies demonstrated that the ASCL2-TDGF1 axis drives the progression of malignant phenotype and metastasis progression in CRC. TDGF1 depletion significantly attenuated the ASCL2 overexpression-induced malignant phenotypes in vitro and xenograft tumor growth and metastasis in vivo. Analysis of clinical samples indicated that expression levels of ASCL2 and TDGF1 were progressively upregulated during CRC progression.
conclusionsThe ASCL2-TDGF1 cascade is a master regulator of CRC metastasis. ASCL2 drives CRC metastasis through direct TDGF1 transcriptional activation, highlighting the pivotal role of TDGF1 as the critical executor of ASCL2-driven metastasis in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.